Search

Your search keyword '"Eberli, Daniel"' showing total 735 results
Start Over Author "Eberli, Daniel" Language english
735 results on '"Eberli, Daniel"'

13. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II—2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer

Author

Tilki, Derya, van den Bergh, Roderick C.N., Briers, Erik, Van den Broeck, Thomas, Brunckhorst, Oliver, Darraugh, Julie, Eberli, Daniel, De Meerleer, Gert, De Santis, Maria, Farolfi, Andrea, Gandaglia, Giorgio, Gillessen, Silke, Grivas, Nikolaos, Henry, Ann M., Lardas, Michael, J.L.H. van Leenders, Geert, Liew, Matthew, Linares Espinos, Estefania, Oldenburg, Jan, van Oort, Inge M., Oprea-Lager, Daniela E., Ploussard, Guillaume, Roberts, Matthew J., Rouvière, Olivier, Schoots, Ivo G., Schouten, Natasha, Smith, Emma J., Stranne, Johan, Wiegel, Thomas, Willemse, Peter-Paul M., and Cornford, Philip

Published
2024
Full Text
View/download PDF

14. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer—2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent

Author

Cornford, Philip, van den Bergh, Roderick C.N., Briers, Erik, Van den Broeck, Thomas, Brunckhorst, Oliver, Darraugh, Julie, Eberli, Daniel, De Meerleer, Gert, De Santis, Maria, Farolfi, Andrea, Gandaglia, Giorgio, Gillessen, Silke, Grivas, Nikolaos, Henry, Ann M., Lardas, Michael, van Leenders, Geert J.L.H., Liew, Matthew, Linares Espinos, Estefania, Oldenburg, Jan, van Oort, Inge M., Oprea-Lager, Daniela E., Ploussard, Guillaume, Roberts, Matthew J., Rouvière, Olivier, Schoots, Ivo G., Schouten, Natasha, Smith, Emma J., Stranne, Johan, Wiegel, Thomas, Willemse, Peter-Paul M., and Tilki, Derya

Published
2024
Full Text
View/download PDF

15. A Systematic Review of the Efficacy and Toxicity of Brachytherapy Boost Combined with External Beam Radiotherapy for Nonmetastatic Prostate Cancer

Author

Slevin, Finbar, Zattoni, Fabio, Checcucci, Enrico, Cumberbatch, Marcus G.K., Nacchia, Antonio, Cornford, Philip, Briers, Erik, De Meerleer, Gert, De Santis, Maria, Eberli, Daniel, Gandaglia, Giorgio, Gillessen, Silke, Grivas, Nikolaos, Liew, Matthew, Linares Espinós, Estefania E., Oldenburg, Jan, Oprea-Lager, Daniela E., Ploussard, Guillaume, Rouvière, Olivier, Schoots, Ivo G., Smith, Emma Jane, Stranne, Johan, Tilki, Derya, Smith, Catrin Tudur, Van Den Bergh, Roderick C.N., Van Oort, Inge M., Wiegel, Thomas, Yuan, Cathy Y., Van den Broeck, Thomas, and Henry, Ann M.

Published
2024
Full Text
View/download PDF

22. Impact of Epithelial Histological Types, Subtypes, and Growth Patterns on Oncological Outcomes for Patients with Nonmetastatic Prostate Cancer Treated with Curative Intent: A Systematic Review

Author

Marra, Giancarlo, van Leenders, Geert J.L.H., Zattoni, Fabio, Kesch, Claudia, Rajwa, Pawel, Cornford, Philip, van der Kwast, Theodorus, van den Bergh, Roderick C.N., Briers, Erik, Van den Broeck, Thomas, De Meerleer, Gert, De Santis, Maria, Eberli, Daniel, Farolfi, Andrea, Gillessen, Silke, Grivas, Nikolaos, Grummet, Jeremy P., Henry, Ann M., Lardas, Michael, Lieuw, Matt, Linares Espinós, Estefania, Mason, Malcolm D., O'Hanlon, Shane, van Oort, Inge M., Oprea-Lager, Daniela E., Ploussard, Guillaume, Rouvière, Olivier, Schoots, Ivo.G., Stranne, Johan, Tilki, Derya, Wiegel, Thomas, Willemse, Peter-Paul M., Mottet, Nicolas, and Gandaglia, Giorgio

Published
2023
Full Text
View/download PDF

27. Mapping European Association of Urology Guideline Practice Across Europe: An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries

Author

Heidegger, Isabel, Resch, Johannes Mischinger Irene, Turba, Simon, Zeder, Robin, Lodeta, Braninimir, Van Praet, Charles, Ghysel, Christophe, Arentsen, Harm C., Beysens, Matthias, Vinckier, Marie-Hélène, Mottrie, Alexandre, de Groote, Ruben, Timev, Aleksandar Ivanov, Georgiev, Marincho Ivanov, Yanev, Krassimir Prodanov, Mladenov, Boris, Ivanov, Atanas Slavchev, Antonov, Petar, Valkanov, Stanislav, Tomašković, Igor, Kulis, Tomislav, Bokarica, Pero, Pavlović, Oliver, Krajina, Vinko, Situm, Marijan, Boban, Toni, Soric, Tomislav, Vidic, Ivan, Benko, Goran, Peršec, Zoran, Sović, Tomislav, Zachoval, Roman, Stejskal, Jiri, Capoun, Otakar, Pitra, Tomáš, Gojdič, Marek, Babjuk, Marek, Novák, Vojtěch, Grepl, Michal, Broul, Marek, Novák, Jan, Lund, Lars, Nordström Joensen, Ulla, Borre, Michael, Veskimäe, Priit, Baum, Peep, Tamm, Toomas, Okas, Rauno, Jämsä, Pyry, Lahdensuo, Kanerva, Siltari, Sirkku, Seikkula, Heikki, Palmberg, Christian, Isotalo, Taina, Fiard, Gaelle, Verrier, Cecile, Wiedemann, Laura, Lecornet, Emilie, Leon, Priscilla, Millet, Clementine, Ponzio, Charles, Ploussard, Guillaume, Xylinas, Evanguelos, Ingels, Alexandre, Bigot, Pierre, Le Corre, Vincent, Audenet, François, Berg, Sebastian, Palisaar, Rein-Jueri, Heidenreich, Axel, Seelemeyer, Felix, Krege, Susanne, Leyh-Bannurah, Sami-Ramzi, Witt, Jörn H., Abdirahman, Ayanle, Truß, Michael C., Kranz, Jennifer, Andreas, Karagiannis, Vassileios, Tzortzis, Andreas, Andreou, Paparidis, Spyridon, Davis, Nikolaos Ferakis Niall F., Keane, Kevin G., Fuentes, Adrian, Scuderi, Simone, Barletta, Francesco, Manfredi, Matteo, Porpiglia, Francesco, Cerruto, Maria Angela, Antonelli, Alessandro, Esperto, Francesco, Rossanese, Marta, Veneziano, Domenico, Castelli, Tommaso, Mantica, Roberto La Rocca Marcello Scarcia Guglielmo, Rebuffo, Silvia, Pomara, Giorgio, Pavan, Nicola, Silvestri, Tommaso, Reale, Giulio Francesco, Polara, Andrea, Falagario, Ugo Giovanni, Carrieri, Giuseppe, Ferrari, Giovanni, Brausi, Maurizio, Orecchia, Luca, Annino, Filippo, Kazlauskas, Gražvydas, Stavridis, Sotir, Radovic, Nenad, Vukovic, Marko, van der Slot, Margaretha Adriana, Bruins, Harman Maxim, van Oort, Inge, Witjes, Fred, van der Poel, Henk, Beisland, Christian, Lilleåsenm, Gunder, Müller, Stig, Haug, Erik S., Dimmen, Magne, Czech, Anna K., Nyk, Lukasz, Jaskulski, Jaroslaw, Ratajczyk, Krzysztof, Azevedo, Nuno, Braga, Isaac, Pereira, João, Lúcio, Rui, Pina, João, da Silva, Edgar Miguel Calvo Loureiro Tavares, Furriel, Frederico, Mota, Paulo, Rodrigues, Miguel, Radavoi, George Daniel, Crisan, Nicolae, Andras, Iulia, Robert, Stoica, Bratu, Ovidiu, Surcel, Cristian, Kotov, Sergei, Malkhasyan, Vigen, Petrov, Sergei, Reva, Sergei, Bumbasirevic, Uros, Kováčik, Viktor, Perečinský, Ivan, Rybár, Ľuboš, Šulgan, Ján, Briš, Lukáš, Jursová, Katarína, Chovan, Miroslav, Kička, Tomáš, Taskovska, Milena, Kovačič, Rok, Miklavžina, Andraž, Alvarez-Maestro, Mario, De Castro, Javier Mayor, Aragón-Chamizo, Juan, Sutil, Raquel Sopeña, Perrello, Carmen Garau, Vilaseca, Antoni, Perez, Jorge Huguet, Ovide, Julia Aumatell, Planas, Jacques, Borque-Fernando, Angel, Sánchez-Izquierdo, Elena, Jimenez, Jose Luis Marenco, Lendínez-Cano, Guillermo, Puche-Sanz, Ignacio, Garcia-Baquero, Rodrigo, Esteban, Mario Domínguez, Pérez-Fentes, Daniel, Serván, Patricia Parra, Koskela, Lotta Renström, Stranne, Johan, Scholtz, Bianca, Torbrand, Christian, Wagenius, Magnus, Ugge, Henrik, Örtegren, Joakim, Langenauer, Janine, Zumstein, Valentin, Schmid, Hans Peter, Rieken, Malte, Saba, Karim, Strebel, Raeto T., Mortezavi, Ashkan, Rentsch, Cyrill, Roth, Beat, Eberli, Daniel, Pascal, Oechslin, Auer, Rebecca, John, Hubert, Thalmann, George N., Baltacı, Sümer, Mungan, Aydın, Sözen, Sinan, Cetin, Serhat, Aslan, Guven, Türkeri, Levent, İzol, Volkan, Demirdağ, Çetin, Ozden, Sami Berk, Toktaş, Gökhan, Sarikaya, Şaban, Tinay, İlker, Müezzinoğlu, Talha, Erbatu, Oguzcan, Sagnak, Levent, Akdoğan, Bülent, Can, Cavit, Şahin, Hayrettin, Yazıcı, Cenk Murat, Volkov, Serhii, Shulyak, Olexandr, Douglas, David, Hemmant, Joshua, El-Taji, Omar, Ahmad, Imran, Nalagatla, Sarika, Janebdar, Husay, Veeratterapillay, Rajan, Rai, Bhavan, Conroy, Samantha, Cumberbatch, Marcus, Malde, Sachin, MacLennan, Steven, Duncan, Eilidh, Dunsmore, Jennifer, Fullwood, Louise, Lumen, Nicolaas, Plass, Karin, Ribal, Maria J., Roobol, Monique J., Nieboer, Daan, Schouten, Natasha, Skolarus, Ted A., Smith, Emma Jane, N'Dow, James, Mottet, Nicolas, and Briganti, Alberto

Published
2023
Full Text
View/download PDF

33. Simultaneous Autophagy and Androgen Receptor Inhibition in a Prostate Cancer Xenograft Model.

Author

Salemi, Souzan, Kranzbühler, Benedikt, Baumgartner, Valentin, Breitenmoser, Lara, Kuzmanov, Aleksandar, Lehner, Fabienne, and Eberli, Daniel

Subjects
ABIRATERONE acetate, BIOLOGICAL models, COMBINATION drug therapy, AUTOPHAGY, DATA analysis, RESEARCH funding, PROSTATE tumors, CHLOROQUINE, XENOGRAFTS, DESCRIPTIVE statistics, MICE, GENE expression, PROSTATE-specific membrane antigen, ANIMAL experimentation, ANALYSIS of variance, STATISTICS, DATA analysis software, ANDROGEN receptors, PHARMACODYNAMICS, CHEMICAL inhibitors
Abstract

Simple Summary: Recent advancements in anticancer drug treatments face significant challenges due to drug resistance, often leading to only partial or short-term responses in patients. Our previous in vitro studies indicated that autophagy is linked to drug resistance in prostate cancer (PCa). Consequently, combination therapies targeting multiple pathways could help overcome resistance and extend treatment efficacy. To validate our earlier findings, we conducted in vivo experiments. Our data demonstrated that combining Abiraterone (Abi) with an autophagy inhibitor such as Chloroquine (Chl) not only reduces autophagy but also suppresses tumors more effectively than Abi alone. Thus, the combination of Abi with autophagy inhibitors represents a promising therapeutic strategy that could potentially offer a novel approach for patients. Objective: Abi, when used in conjunction with prednisone, is an established treatment for advanced PCa. Our goal was to explore the level of autophagy induced by Abi treatment, both alone and in combination with the autophagy inhibitor Chl, in a castrated mouse xenograft model. Methods: LNCaP cells were injected into the left and right sides of the back of nude mice that had been previously castrated. Mice were divided into four groups and treated daily with intraperitoneal injections of vehicle (control), Abi (10 mg/kg), Abi (10 mg/kg) combined with Chl (10 mg/kg), or Chl (10 mg/kg), and were monitored for periods of 2 and 3 weeks. Results: A significant reduction in tumor weight was observed in mice treated with the combination therapy, as opposed to those receiving vehicle control, Abi, or Chl alone. Mice receiving Abi + Chl exhibited reduced expression of ATG5, Beclin 1, and LC3 punctuations, along with an increase in P62, as determined by immunofluorescence and WES analysis. AR expression decreased significantly in all treatment groups compared to the control. PSMA expression was highest in the vehicle and combined treatment groups after 3 weeks, with a significant reduction observed with Chl treatment. Conclusions: These findings demonstrate that Abi + Chl treatment lowers autophagy levels and suppresses tumors more effectively than Abi alone. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

49. Illumination matters part I: comparative analysis of light sources and illumination in flexible ureteroscopy-fundamental findings from a PEARLS analysis.

Author

Kwok, Jia-Lun, De Coninck, Vincent, Corrales, Mariela, Sierra, Alba, Panthier, Frédéric, Ventimiglia, Eugenio, Gauhar, Vineet, Schmid, Florian Alexander, Hunziker, Manuela, Poyet, Cédric, Eberli, Daniel, Traxer, Olivier, and Keller, Etienne Xavier

Subjects
LIGHT sources, COLOR temperature, LIGHTING, COLORIMETRY, LUMINOUS flux
Abstract

Purpose: Illumination characteristics of flexible ureteroscopes have been evaluated in air, but not in saline, the native operative medium for endourology. The aim was to evaluate light properties of contemporary ureteroscopes in air versus saline, light distribution analysis, and color temperature. Methods: We evaluated the Storz Flex-Xc and Flex-X2s, Olympus V3 and P7, Pusen 7.5F and 9.2F, and OTU WiScope using a 3D printed black target board in-vitro model submerged in saline. A spectrometer was used for lux and color temperature measurements at different opening locations. Results: Illuminance was higher in saline compared to air (5679 vs. 5205 lx with Flex-Xc, p = 0.02). Illuminance in saline differed between ureteroscopes (ANOVA p < 0.001), with highest for the Flex-Xc at 100% brightness setting (5679 lx), followed by Pusen 9.2F (5280 lx), Flex-X2s (4613 lx), P7 (4371 lx), V3 (2374 lx), WiScope (582 lx) and finally Pusen 7.5F (255 lx). The same ranking was found at 50% brightness setting, with the highest ureteroscope illuminance value 34 times that of the scope with lowest illuminance. Most scopes had maximum illuminance off center, with skewness. Three scopes had two light sources, with one light source for all other scopes. Inter-scope comparisons revealed significant differences of color temperature (ANOVA p < 0.001). Conclusion: The study demonstrates the presence of inhomogeneous light spread as well as large differences in illumination properties of ureteroscopes, possibly impacting on the performance of individual scopes in vivo. Additionally, the study suggests that future studies on illumination characteristics of flexible ureteroscopes should ideally be done in saline, and no longer in air. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

50. Focal therapy with high‐intensity focused ultrasound for prostate cancer: 3‐year outcomes from a prospective trial.

Author

Kaufmann, Basil, Raess, Elisa, Schmid, Florian A., Bieri, Uwe, Scherer, Thomas P., Elleisy, Moustafa, Donati, Olivio F., Rupp, Niels J., Moch, Holger, Gorin, Michael A., Mortezavi, Ashkan, and Eberli, Daniel

Subjects
HIGH-intensity focused ultrasound, PROSTATE cancer, PROSTATE-specific antigen, CANCER prognosis, PROSPECTIVE memory, LIFE expectancy
Abstract

Objective: To assess the oncological and functional outcomes of focal high‐intensity focused ultrasound (HIFU) in treating localised prostate cancer (PCa), a 3‐year prospective study was undertaken using periodic post‐ablation saturation biopsies. Patients and Methods: Men with two or fewer lesions of grade group (GG) ≤3 PCa were eligible for participation. Additional criteria included a prostate‐specific antigen (PSA) level of ≤15 ng/mL, clinical T1c‐T2, and a life expectancy of ≥10 years. The primary endpoint was failure‐free survival (FFS), defined as absence of clinically significant PCa (csPCa) in‐ or out‐of‐field on protocol‐mandated saturation biopsy, no whole‐gland or systemic salvage treatment, PCa metastasis, or PCa‐related death. Results are reported using two distinct definitions of csPCa: (i) the presence of any GG ≥2 and (ii) any GG ≥3 or core involvement of ≥6 mm. Secondary endpoints were functional patient‐reported outcome measures addressing urinary, sexual, and bowel function. Results: A total of 91 patients were included: six (7%) with GG1 and 85 (93%) with GG ≥2. In all, 83 (91%) underwent at least one follow‐up biopsy. Biopsy attendance at 6, 12, and 36 months was 84%, 67%, and 51%, respectively. The FFS at these time points for any GG ≥2 PCa was 79% (95% confidence interval [CI] 80–88%), 57% (95% CI 48–69%) and 44% (95% CI 34–56%), respectively. Using the second definition, FFS were 88% (95% CI 81–95%), 70% (95% CI 61–81%) and 65% (95% CI 55–77%), respectively. The 3‐year cancer‐specific survival was 100%, and freedom from metastasis was 99%. Magnetic resonance imaging (MRI) (negative predictive value of up to 89%, 95% CI 84–93%) and relative decrease of PSA values (P = 0.4) performed poorly in detecting residual disease. Urinary and bowel assessment returned to baseline questionnaire scores within 3 months. In all, 17 (21%) patients reported meaningful worsening in erectile function. A significant decrease of PCa related anxiety was observed. Conclusions: Focal HIFU treatment for localised PCa shows excellent functional outcomes with half of the patients remaining cancer‐free after 3 years. Whole‐gland treatment was avoided in 81%. Early follow‐up biopsies are crucial to change or continue the treatment modality at the right time, while the use of MRI and PSA in detecting PCa recurrence is uncertain. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results